Khiron Launches Kuida CBD Skincare Products Into Hong Kong Market

Khiron Life Sciences (TSXV: KHRN) is going to Asia. The company announced this morning that it has signed a distribution deal for its Kuida CBD cosmetics brands with that of DNO Group, a leading distributor within the Asian market with over 50,000 points of sale within the Asian region. Distribution of Kuida products are expected to commence in the fourth quarter of 2020.

Under the distribution agreement, Khiron will see its Kuida line of skincare products sold through DNO Group’s network of pharmacy, beauty retail and online markets within the territory of Hong Kong. The agreement is a landmark for the company, given that the Asian region is the largest purchaser of skincare products, accounting for 53% of global sales.

The Hong Kong market itself contains a population of 7.2 million people, while also serving as an international hub for the mainland. Hong Kong itself is believed to have accounted for roughly $2.7 billion within the cosmetics and personal care segment in 2018 alone, while continuing to expand annually.

"With this distribution deal we establish a significant footprint in Hong Kong for our Kuida brand and gain access to the Asian Pacific beauty and skincare market, the world's largest region for skincare products. DNO Group have a large distribution network of over 50,000 points of sales in the region, including prominent pharmacy, beauty retail and online channels that we know from experience in other jurisdictions are where our customers are choosing to purchase Kuida products. Importantly, DNO Group brings valuable insight into the Asian consumer profile, further supporting the impact of the brand roll-out in Hong Kong."

A total of seven SKU’s under the Kuida brand are to be distributed into the Hong Kong market by DNO Group under the distribution agreement. The first orders are anticipated to occur in the fourth quarter of 2020. The launch of Kuida products within the Hong Kong market will be supported by product training, CBD education, consumer marketing and brand activation.

Khiron Life Sciences last traded at $0.48 on the TSX Venture.


FULL DISCLOSURE: Khiron Life Sciences is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover Khiron Life Sciences on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.

Video Articles

Is Gold’s Bull Market About to Hit Junior Stocks? | Ken Armstrong – Westhaven Gold

Surge Battery Metals: The Nevada North Lithium PEA

Silver @ $36 & We’re Still 200M Oz Short | Paul Andre Huet – Americas Gold and Silver

Recommended

Goliath Resources Closes Out Funding Round With Total Gross Proceeds Of $27.1 Million

Silver47 Kickstarts 4,000 Metre Drill Campaign At Red Mountain Project

Related News

Khiron Passes 1,000 Patient Prescriptions in Colombia, Issues Corporate Update

Khiron Life Sciences (TSXV: KHRN) this morning issued a corporate update, chief among which included...

Monday, July 27, 2020, 09:00:38 AM

Khiron Life Sciences Sees CFO Resign, Appoints Third-Party Interim

Khiron Life Sciences Corp. (TSXV: KHRN) announced on Friday after the closing bell that its...

Monday, October 4, 2021, 10:41:00 AM

Khiron Life Sciences X Nimbus Health

Khiron Life Sciences (TSXV: KHRN, OTCQX: KHRNF, Frankfurt: A2JMZC) is the latest cannabis company to...

Sunday, August 16, 2020, 09:00:00 AM

Khiron Life Sciences Looks To Acquire PharmaDrug’s German Subsidiary For $2.0 Million

Khiron Life Sciences Corp. (TSXV: KHRN) announced today the plan to acquire Pharmadrug GmbH, a...

Tuesday, May 31, 2022, 10:34:00 AM

Khiron Signs Exclusive Partnership with Rappi, The Amazon Of South America

Khiron Life Sciences (TSXV: KHRN) this morning announced the significant development of establishing an exclusive...

Friday, September 4, 2020, 08:17:02 AM